ArticleDiscover oncology2023

A MRI-based radiomics model for predicting the response to anlotinb combined with temozolomide in recurrent malignant glioma patients.

Yurong Li et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.